Our Technology

Filament Health operates one of the first GMP facilities in the world to also have a Health Canada Dealer’s License. This enables us to propagate psychedelic plants, conduct genetic research, perform extraction procedures, run in-house trials, and distribute IP and drug candidates. Our research program intends to include all controlled natural psychedelics including DMT, harmaline, mescaline, and more.

GMP Facility with Health Canada Dealer’s License

These certifications enable Filament Health to supply in-house trials, and distribute IP and drug candidates to drug developers, researchers, and other licensed parties.

3,500 ft2 manufacturing, research, and development facility on BCIT campus

Health Canada Dealer’s License (#6-1289) permits:

Propagation, extraction and production

Distribution and sale

Ongoing propagation and cultivation research program to identify best strains and genetics
License amendment submitted to include all controlled natural psychedelics (DMT, harmaline, mescaline, etc.)
Multiple ongoing supply discussions for products and IP

Drug Development Platform

While advancing our leading drug candidates, we will continue to build out our discovery pipeline, leaning on our natural extraction expertise to access the vast potential of psychoactive plant and fungi species.

With hundreds of species to be explored, and the possibility of proving the entourage effect, we believe there is potential for many new natural psychedelic medicines to become available in the near term.

Filament Health’s drug development platform has led to the discovery and patent filings on important methods of extraction and purification. Unlike synthetic drugs which can have thousands of variations, there are few effective ways to extract and purify the compounds in plants. We believe this is important intellectual property that must be handled with great care.

Overview of Filament’s patent family

Natural Psychedelic Processing Steps



Grow botanical psychedelics



Remove target compounds from biomass



Remove undesirable elements



Exact concentrations



Different methods and forms

Patent Family at a Glance

Patent Family Deeper Dive

Our Clinical Trials

One drug platform – many trials.

Filament’s platform allows for possibly hundreds of drugs to be discovered and run through clinical trials by Filament or in partnership with other companies.

Two of Filament’s unique patent-protected drug candidates will enter two separate FDA investigator-initiated human clinical trials in 2021.

1. Patents held in Filament’s wholly-owned subsidiary